A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method

A key challenge in phase I trials is maintaining rapid escalation in order to avoid exposing too many patients to sub-therapeutic doses, while preserving safety by limiting the frequency of toxic events.